Initial Combination Therapy Compared With Monotherapy in Diabetic Hypertensive Patients
Autor: | James R. Sowers, Yodit Seifu, Guido Lastra, Ricardo Rocha, Nora Crikelair, Drew Griffin Levy |
---|---|
Rok vydání: | 2008 |
Předmět: |
Blood Glucose
Male medicine.medical_specialty Combination therapy Endocrinology Diabetes and Metabolism Urology Tetrazoles Blood Pressure Severity of Illness Index law.invention Hydrochlorothiazide Double-Blind Method Randomized controlled trial law Diabetes mellitus Internal Medicine medicine Humans Hypoglycemic Agents Diuretics Antihypertensive Agents Aged Dose-Response Relationship Drug biology business.industry C-reactive protein Valine Middle Aged medicine.disease Original Papers C-Reactive Protein Diabetes Mellitus Type 1 Treatment Outcome Blood pressure Diabetes Mellitus Type 2 Valsartan Tolerability Hypertension Physical therapy biology.protein Drug Therapy Combination Female Cardiology and Cardiovascular Medicine business Angiotensin II Type 1 Receptor Blockers Follow-Up Studies medicine.drug |
Zdroj: | J Clin Hypertens (Greenwich) |
ISSN: | 1751-7176 1524-6175 |
Popis: | Subgroup analyses were performed for the diabetic and nondiabetic cohorts from 3 randomized clinical trials that had evaluated the systolic blood pressure (SBP)-lowering efficacy and tolerability of an angiotensin receptor blocker, valsartan, alone or in combination with hydrochlorothiazide to determine when and how to initiate combination therapy in hypertensive patients with diabetes. Blood pressure reductions achieved with monotherapy were compared with combination therapy in the diabetic and nondiabetic cohorts. In addition, multivariate models were developed to predict the likelihood of the goal SBP of < 130 mm Hg being reached in a diabetic patient with monotherapy or combination therapy across the range of baseline SBP values. In 2 of the 3 trials, comparable reductions in SBP were seen in the diabetic and nondiabetic cohorts. In all 3 studies, however, combination therapy provided greater blood pressure-lowering efficacy than monotherapy. The probability of achieving goal SBP was greater for diabetic patients started on combination therapy compared with monotherapy. |
Databáze: | OpenAIRE |
Externí odkaz: |